Do analysts recommend AVIR or FTLF?

FitLife Brands has a consensus price target of $21.50, indicating a potential upside of 109.76%. Given FitLife Brands' higher probable upside, analysts clearly believe FitLife Brands is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 FitLife Brands 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

FitLife Brands (FTLF) Competitors

$10.25 0.00 (0.00%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$10.35 +0.10 (+0.98%)

As of 07/24/2026 07:34 PM Eastern

Compare

FTLF vs. AVIR, AUTL, LXEO, ENTA, and DMAC

Should you buy FitLife Brands stock or one of its competitors? MarketBeat compares FitLife Brands with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FitLife Brands include Atea Pharmaceuticals (AVIR), Autolus Therapeutics (AUTL), Lexeo Therapeutics (LXEO), Enanta Pharmaceuticals (ENTA), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry.

How does FitLife Brands compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Atea Pharmaceuticals has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

FitLife Brands has a net margin of 6.64% compared to Atea Pharmaceuticals' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
FitLife Brands	6.64%	18.31%	8.21%

FitLife Brands has a consensus price target of $21.50, indicating a potential upside of 109.76%. Given FitLife Brands' higher probable upside, analysts clearly believe FitLife Brands is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
FitLife Brands	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Atea Pharmaceuticals had 1 more articles in the media than FitLife Brands. MarketBeat recorded 2 mentions for Atea Pharmaceuticals and 1 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 1.87 beat Atea Pharmaceuticals' score of 0.59 indicating that FitLife Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Atea Pharmaceuticals	Positive
FitLife Brands	Very Positive

FitLife Brands has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
FitLife Brands	$81.46M	1.18	$6.33M	$0.60	17.08

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 61.7% of FitLife Brands shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

FitLife Brands beats Atea Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does FitLife Brands compare to Autolus Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

FitLife Brands has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.12	-$287.53M	-$1.09	N/A
FitLife Brands	$81.46M	1.18	$6.33M	$0.60	17.08

Autolus Therapeutics currently has a consensus price target of $8.75, indicating a potential upside of 503.45%. FitLife Brands has a consensus price target of $21.50, indicating a potential upside of 109.76%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Autolus Therapeutics is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
FitLife Brands	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 2.3% of FitLife Brands shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 61.7% of FitLife Brands shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Autolus Therapeutics has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

FitLife Brands has a net margin of 6.64% compared to Autolus Therapeutics' net margin of -311.98%. FitLife Brands' return on equity of 18.31% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
FitLife Brands	6.64%	18.31%	8.21%

In the previous week, Autolus Therapeutics had 2 more articles in the media than FitLife Brands. MarketBeat recorded 3 mentions for Autolus Therapeutics and 1 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 1.87 beat Autolus Therapeutics' score of 1.16 indicating that FitLife Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Autolus Therapeutics	Positive
FitLife Brands	Very Positive

Summary

FitLife Brands beats Autolus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does FitLife Brands compare to Lexeo Therapeutics?

FitLife Brands (NASDAQ:FTLF) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

FitLife Brands has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.18	$6.33M	$0.60	17.08
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

FitLife Brands currently has a consensus target price of $21.50, suggesting a potential upside of 109.76%. Lexeo Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 302.36%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

FitLife Brands has a net margin of 6.64% compared to Lexeo Therapeutics' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 61.7% of FitLife Brands shares are held by insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Lexeo Therapeutics had 4 more articles in the media than FitLife Brands. MarketBeat recorded 5 mentions for Lexeo Therapeutics and 1 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 1.87 beat Lexeo Therapeutics' score of 1.10 indicating that FitLife Brands is being referred to more favorably in the media.

Company	Overall Sentiment
FitLife Brands	Very Positive
Lexeo Therapeutics	Positive

FitLife Brands has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

Summary

FitLife Brands beats Lexeo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does FitLife Brands compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

FitLife Brands has a net margin of 6.64% compared to Enanta Pharmaceuticals' net margin of -89.56%. FitLife Brands' return on equity of 18.31% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
FitLife Brands	6.64%	18.31%	8.21%

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 2.3% of FitLife Brands shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 61.7% of FitLife Brands shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Enanta Pharmaceuticals had 2 more articles in the media than FitLife Brands. MarketBeat recorded 3 mentions for Enanta Pharmaceuticals and 1 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 1.87 beat Enanta Pharmaceuticals' score of 1.23 indicating that FitLife Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Positive
FitLife Brands	Very Positive

FitLife Brands has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.69	-$81.89M	-$2.59	N/A
FitLife Brands	$81.46M	1.18	$6.33M	$0.60	17.08

Enanta Pharmaceuticals presently has a consensus price target of $20.29, suggesting a potential upside of 58.73%. FitLife Brands has a consensus price target of $21.50, suggesting a potential upside of 109.76%. Given FitLife Brands' higher probable upside, analysts plainly believe FitLife Brands is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
FitLife Brands	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Enanta Pharmaceuticals has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Summary

FitLife Brands beats Enanta Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does FitLife Brands compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

FitLife Brands has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
FitLife Brands	$81.46M	1.18	$6.33M	$0.60	17.08

DiaMedica Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

DiaMedica Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 78.04%. FitLife Brands has a consensus price target of $21.50, indicating a potential upside of 109.76%. Given FitLife Brands' higher possible upside, analysts plainly believe FitLife Brands is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
FitLife Brands	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 2.3% of FitLife Brands shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 61.7% of FitLife Brands shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

FitLife Brands has a net margin of 6.64% compared to DiaMedica Therapeutics' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
FitLife Brands	6.64%	18.31%	8.21%

In the previous week, DiaMedica Therapeutics and DiaMedica Therapeutics both had 1 articles in the media. DiaMedica Therapeutics' average media sentiment score of 1.87 equaled FitLife Brands'average media sentiment score.

Company	Overall Sentiment
DiaMedica Therapeutics	Very Positive
FitLife Brands	Very Positive

Summary

FitLife Brands beats DiaMedica Therapeutics on 9 of the 13 factors compared between the two stocks.

Get FitLife Brands News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTLF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTLF vs. The Competition

Export

Metric	FitLife Brands	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$96.26M	$8.50B	$6.86B	$12.25B
Dividend Yield	N/A	2.52%	2.67%	9.79%
P/E Ratio	12.97	18.51	27.14	23.64
Price / Sales	1.18	5.77	517.01	89.03
Price / Cash	8.79	18.17	50.54	59.64
Price / Book	2.20	3.19	10.28	6.07
Net Income	$6.33M	$230.22M	$3.60B	$331.99M
7 Day Performance	-7.32%	21.66%	-1.27%	-0.63%
1 Month Performance	-14.08%	20.22%	-0.37%	-2.00%
1 Year Performance	-20.54%	-4.55%	18.30%	13.62%

FitLife Brands Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTLF FitLife Brands	4.425 of 5 stars	$10.25 flat	$21.50 +109.8%	-22.8%	$96.26M	$81.46M	12.97	20	Positive News Gap Up
AVIR Atea Pharmaceuticals	0.6836 of 5 stars	$4.81 -1.2%	N/A	+26.5%	$384.93M	N/A	N/A	70
AUTL Autolus Therapeutics	2.3685 of 5 stars	$1.44 -1.7%	$8.75 +507.6%	-45.1%	$383.27M	$92.62M	N/A	330	Positive News
LXEO Lexeo Therapeutics	1.9554 of 5 stars	$4.87 +4.5%	$18.75 +285.0%	+27.0%	$382.40M	N/A	N/A	58	News Coverage High Trading Volume
ENTA Enanta Pharmaceuticals	2.5832 of 5 stars	$13.06 -2.7%	$20.29 +55.3%	+74.1%	$379.79M	$65.32M	N/A	160	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTLF) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FitLife Brands (FTLF) Competitors

FTLF vs. AVIR, AUTL, LXEO, ENTA, and DMAC

How does FitLife Brands compare to Atea Pharmaceuticals?

Summary

How does FitLife Brands compare to Autolus Therapeutics?

Summary

How does FitLife Brands compare to Lexeo Therapeutics?

Summary

How does FitLife Brands compare to Enanta Pharmaceuticals?

Summary

How does FitLife Brands compare to DiaMedica Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTLF vs. The Competition

FitLife Brands Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FitLife Brands (FTLF) Competitors

FTLF vs. AVIR, AUTL, LXEO, ENTA, and DMAC

How does FitLife Brands compare to Atea Pharmaceuticals?

Which has more volatility & risk, AVIR or FTLF?

Is AVIR or FTLF more profitable?

Do analysts recommend AVIR or FTLF?

Does the media prefer AVIR or FTLF?

Which has stronger valuation & earnings, AVIR or FTLF?

Do institutionals and insiders believe in AVIR or FTLF?

Summary

How does FitLife Brands compare to Autolus Therapeutics?

Which has better valuation & earnings, AUTL or FTLF?

Do analysts rate AUTL or FTLF?

Do institutionals and insiders hold more shares of AUTL or FTLF?

Which has more risk and volatility, AUTL or FTLF?

Is AUTL or FTLF more profitable?

Does the media prefer AUTL or FTLF?

Summary

How does FitLife Brands compare to Lexeo Therapeutics?

Which has higher earnings & valuation, FTLF or LXEO?

Do analysts recommend FTLF or LXEO?

Is FTLF or LXEO more profitable?

Do insiders and institutionals hold more shares of FTLF or LXEO?

Does the media refer more to FTLF or LXEO?

Which has more risk and volatility, FTLF or LXEO?

Summary

How does FitLife Brands compare to Enanta Pharmaceuticals?

Is ENTA or FTLF more profitable?

Do insiders and institutionals have more ownership in ENTA or FTLF?

Does the media favor ENTA or FTLF?

Which has better valuation and earnings, ENTA or FTLF?

Do analysts rate ENTA or FTLF?

Which has more volatility and risk, ENTA or FTLF?

Summary

How does FitLife Brands compare to DiaMedica Therapeutics?

Which has higher valuation & earnings, DMAC or FTLF?

Which has more risk and volatility, DMAC or FTLF?

Do analysts recommend DMAC or FTLF?

Do insiders and institutionals believe in DMAC or FTLF?

Is DMAC or FTLF more profitable?

Does the media prefer DMAC or FTLF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTLF vs. The Competition

FitLife Brands Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools